Clinical pharmacology issues relevant to the dosing and toxicity of chemotherapy drugs in the elderly

Oncologist

Volumn 10, Issue 8, 2005, Pages 602-612

  Wasil, Tarun ^a   Lichtman, Stuart M ^b  

^a LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chemotherapy; Elderly; Pharmacology; Toxicity

Indexed keywords

AMIFOSTINE; ANASTROZOLE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450 3A4; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; EXEMESTANE; FLUOROURACIL; FOLINIC ACID; FULVESTRANT; GEFITINIB; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMATINIB; IRINOTECAN; LETROZOLE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEMETREXED; PREDNISONE; RITUXIMAB; TAMOXIFEN CITRATE; TOPOTECAN; TRASTUZUMAB; VINCRISTINE;

ACNE; ADVANCED CANCER; AGING; ALLERGY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; COMORBIDITY; DIARRHEA; DOSE KIDNEY FUNCTION RELATION; DRUG ABSORPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; EARLY DIAGNOSIS; FUNCTIONAL ASSESSMENT; GERIATRICS; HEMATOPOIESIS; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OSTEOLYSIS; OTOTOXICITY; OVARY CANCER; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; VOMITING;

AGED; AGED, 80 AND OVER; AGING; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; NEOPLASMS;

EID: 26444514977     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.10-8-602     Document Type: Review

References (149)

1. Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer 1997;80:1273-1283.
2. Edwards BK, Howe HL, Ries LA et al. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer 2002;94:2766-2792.
3. Hamerman D. Toward an understanding of frailty. Ann Intern Med 1999;130:945-950.
4. Baker SD, Grochow LB. Pharmacology of cancer chemotherapy in the older person. Clin Geriatr Med 1997;13:169-183.
5. DeMario MD, Ratain MJ. Oral chemotherapy, rationale and future directions. J Clin Oncol 1998;16:2557-2567.
6. Richardson JL, Shelton DR, Krailo M et al. The effect of compliance with treatment on survival among patients with hematologic malignancies. J Clin Oncol 1990;8:356-364.
7. Lebovits AH, Strain JJ, Schleifer SJ et al. Patient noncompliance with self-administered chemotherapy. Cancer 1990;65:17-22.
8. Kastrissios H, Blaschke TF. Medication compliance as a feature in drug development. Annu Rev Pharmacol Toxicol 1997;37:451-475.
9. Urquhart J. Patient compliance with crucial drug regimens: implications for prostate cancer. Eur Urol 1996;29(suppl 2):124-131.
10. Egorin MJ. Cancer pharmacology in the elderly. Semin Oncol 1993;20:43-49.
11. Schrijvers D, Highley M, De Bruyn E et al. Role of red blood cells in pharmacokinetics of chemotherapeutic agents. Anticancer Drugs 1999;10:147-153.
12. Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 2003;348:538-549.
13. Extermann M, Yoder J, Overcash J et al. Influence of p450-metabolized concomitant medications on toxicity from chemotherapy in older cancer patients. Proc Am Soc Clin Oncol 2003;22:2937a.
14. Flockhart D. Cytochrome P450 Drug-Interaction Table. Available at http://medicine.iupui.edu/flockhart/. Accessed January 17, 2005.
15. Flockhart DA, Tanus-Santos JE. Implications of cytochrome P450 interactions when prescribing medication for hypertension. Arch Intern Med 2002;162:405-412.
16. Flockhart DA, Rae JM. Cytochrome P450 3A pharmacogenetics: the road that needs traveled. Pharmacogenomics J 2003;3:3-5.
17. Brenner BM, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 1982;307:652-659.
18. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
19. Jelliffe RW. Estimation of creatinine clearance when urine cannot be collected. Lancet 1971;1:975-976.
20. Marx GM, Blake GM, Galani E et al. Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients. Ann Oncol 2004;15:291-295.
21. Kintzel PE, Dorr RT. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev 1995;21:33-64.
22. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383.
23. Yancik R, Wesley MN, Ries LA et al. Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study. Cancer 1998;82:2123-2134.
24. Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 1994;120:104-110.
25. Rockwood K, Stadnyk K, MacKnight C et al. A brief clinical instrument to classify frailty in elderly people. Lancet 1999;353:205-206.
26. Extermann M. Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol 2000;35:181-200.
27. Extermann M, Overcash J, Lyman GH et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998;16:1582-1587.
28. Repetto L, Fratino L, Audisio RA et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol 2002;20:494-502.
29. Fried LP, Tangen CM, Walston J et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001;56:M146-M156.
30. Cohen HJ, Feussner JR, Weinberger M et al. A controlled trial of inpatient and outpatient geriatric evaluation and management. N Engl J Med 2002;346:905-912.
31. Ingram SS, Seo PH, Martell RE et al. Comprehensive assessment of the elderly cancer patient: the feasibility of self-report methodology. J Clin Oncol 2002;20:770-775.
32. Extermann M. Assessing elderly cancer patients. The SIOG Task Force on Oncogeriatric Assessment presents its findings to the experts. Cancer Futures 2003;2:155-157.
33. Boggs DR, Patrene KD. Hematopoiesis and aging III: Anemia and a blunted erythropoietic response to hemorrhage in aged mice. Am J Hematol 1985;19:327-338.
34. Rothstein G, Christensen RD, Nielsen BR. Kinetic evaluation of the pool sizes and proliferative response of neutrophils in bacterially challenged aging mice. Blood 1987;70:1836-1841.
35. Baraldi-Junkins CA, Beck AC, Rothstein G. Hematopoiesis and cytokines. Relevance to cancer and aging. Hematol Oncol Clin North Am 2000;14:45-61, viii.
36. Ania BJ, Suman VJ, Fairbanks VF et al. Incidence of anemia in older people: an epidemiologic study in a well defined population. J Am Geriatr Soc 1997;45:825-831.
37. Chaves PH, Ashar B, Guralnik JM et al. Looking at the relationship between hemoglobin concentration and prevalent mobility difficulty in older women. Should the criteria currently used to define anemia in older people be reevaluated? J Am Geriatr Soc 2002;50:1257-1264.
38. Ania BJ, Suman VJ, Fairbanks VF et al. Prevalence of anemia in medical practice: community versus referral patients. Mayo Clin Proc 1994;69:730-735.
39. Balducci L, Yates J. General guidelines for the management of older patients with cancer. Oncology (Williston Park) 2000;14:221-227.
40. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004;100:228-237.
41. Schild SE, Stella PJ, Geyer SM et al. The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol 2003;21:3201-3206.
42. Argiris A, Li Y, Murphy BA et al. Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy. J Clin Oncol 2004;22:262-268.
43. Lyman GH, Delgado DJ. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 2003;98:2402-2409.
44. Balducci L, Repetto L. Increased risk of myelotoxicity in elderly patients with non-Hodgkin lymphoma. Cancer 2004;100:6-11.
45. Balducci L, Lyman GH. Patients aged > or = 70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy. J Clin Oncol 2001;19:1583-1585.
46. Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 2003;21:4524-4531.
47. Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 1981;304:101-105.
48. Chrischilles EA, Link BK, Scott SD et al. Factors associated with early termination of CHOP therapy and the impact on survival among patients with chemosensitive intermediate-grade non-Hodgkin'slymphoma. Cancer Control 2003;10:396-403.
49. Dixon DO, Neilan B, Jones SE et al. Effect of age on therapeutic outcome in advanced diffuse histocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol 1986;4:295-305.
50. Hutchins LF, Unger JM, Crowley JJ et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999;341:2061-2067.
51. Muss H, Woolf S, Berry D et al. Older women with node positive (N+) breast cancer (BC) get similar benefits from adjuvant chemotherapy (Adj) as younger patients (pts): the Cancer and Leukemia Group B (CALGB) experience. Proc Am Soc Clin Oncol 2003;22:11a.
52. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;352:930-942.
53. Hurria A, Leung D, Trainor K et al. Factors influencing treatment patterns of breast cancer patients age 75 and older. Crit Rev Oncol Hematol 2003;46:121-126.
54. Hughes KS, Schnaper L, Berry D et al. Comparison of lumpectomy plus tamoxifen with and without radiotherapy (RT) in women 70 years of age or older who have clinical stage I, estrogen receptor positive (ER+) breast carcinoma. Proc Am Soc Clin Oncol 2001;20:93a.
55. Dees EC, O'Reilly S, Goodman SN et al. A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Invest 2000;18:521-529.
56. Balducci L. Geriatric oncology: challenges for the new century. Eur J Cancer 2000;36:1741-1754.
57. Crivellari D, Bonetti M, Castiglione-Gertsch M et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. J Clin Oncol 2000;18:1412-1422.
58. Lichtman SM, Zaheer W, Gal D et al. No increased risk of Taxol toxicity in older patients. J Am Geriatr Soc 1996;44:472-474.
59. Del Mastro L, Perrone F, Repetto L et al. Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer). Ann Oncol 2005;16:253-258.
60. Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431-1439.
61. Buzdar AU. 'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer-efficacy overview. J Steroid Biochem Mol Biol 2003;86:399-403.
62. Klijn J, for the ATAC Trialists' Group. The ATAC (anastrozole, Tamoxifen, Alone or in Combination) trial. An efficacy update, focusing on breast cancer (BC) events, based on a median follow-up of 47 months. Proc Am Soc Clin Oncol 2003;22:338a.
63. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-62.
64. Goss PE, Ingle JN, Martino S et al. A randomized trial of letrozole in post-menopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-1802.
65. Ingle JN. Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings. Clin Cancer Res 2005;11:900s-905s.
66. Nabholtz JM, Buzdar A, Pollak M et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000;18:3758-3767.
67. Mouridsen H, Gershanovich M, Sun Y et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;19:2596-2606.
68. Vogel C, Cobleigh MA, Tripathy D et al. First-line, single-agent Herceptin® (trastuzumab) in metastatic breast cancer: a preliminary report. Eur J Cancer 2001;37(suppl 1):S25-S29.
69. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
70. Burstein H, Kuter I, Campos SM et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001;19:2722-2730.
71. Sledge GW Jr. Gemcitabine combined with paclitaxel or paclitaxel/trastuzumab in metastatic breast cancer. Semin Oncol 2003;30(suppl 3):19-21.
72. O'Shaughnessy JA. Potential of capecitabine as first-line therapy for metastatic breast cancer: dosing recommendations in patients with diminished renal function. Ann Oncol 2002;13:983.
73. O'Shaughnessy JA, Blum J, Moiseyenko V et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001;12:1247-1254.
74. Poole C, Gardiner J, Twelves C et al. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients. Cancer Chemother Pharmacol 2002;49:225-234.
75. Bajetta E, Procopio G, Celio L et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005;23:2155-2161.
76. Seidman AD, Berry D, Cirrincione C et al. CALGB 9840: phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. J Clin Oncol 2004;22:512.
77. Perez EA, Vogel CL, Irwin DH et al. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 2001;19:4216-4223.
78. Sundararajan V, Grann VR, Jacobson JS et al. Variations in the use of adjuvant chemotherapy for node-positive colon cancer in the elderly: a population-based study. Cancer J 2001;7:213-218.
79. Sundararajan V, Mitra N, Jacobson JS et al. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med 2002;136:349-357.
80. Neugut AI, Fleischauer AT, Sundararajan V et al. Use of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly: a population-based study. J Clin Oncol 2002;20:2643-2650.
81. Sargent DJ, Goldberg RM, Jacobson SD et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001;345:1091-1097.
82. Stein BN, Petrelli NJ, Douglass HO et al. Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer 1995;75:11-17.
83. Chiara S, Nobile MT, Vincenti M et al. Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy. Cancer Chemother Pharmacol 1998;42:336-340.
84. de Gramont A, Banzi M, Navarro M et al. Oxaliplatin/5-FU/LV in adjuvant colon cancer: results of the international randomized MOSAIC trial. Proc Am Assoc Cancer Res 2003;22:1015a.
85. Tabah-Fisch I, Maindrault-Goebel F, Benavides M et al. Oxaliplatin/5FU/LV is feasible, safe and active in elderly colorectal cancer (CRC) patients. Proc Am Soc Clin Oncol 2002;21:556a.
86. Carreca I, Comella P, Maiorino L et al. Oral capecitabine plus oxaliplatin (XELOX regimen) in elderly patients with advanced colorectal carcinoma (ACC). Southern Italy Cooperative Oncology Group (SICOG 0108) phase II study. Proc Am Soc Clin Oncol 2003;22:2939a.
87. Aparicio T, Desrame J, Lecomte T et al. Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly. Br J Cancer 2003;89:1439-1444.
88. Twelves C, Wong A, Nowacki MP et al. Capecitabine as adjurant treatment for stage III colon cancer. N Engl J Med 2005;352:2696-2704.
89. Douillard JY, Sobrero A, Carnaghi C et al. Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy. Ann Oncol 2003;14(suppl 2):ii7-ii12.
90. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-237.
91. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
92. Takimoto CH, Remick SC, Sharma S et al. Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working group. Semin Oncol 2003;30:20-25.
93. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-914.
94. Venook AP, Enders Klein C, Fleming G et al. A phase 1 and pharmaco-kinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann Oncol 2003;14:1783-1790.
95. Rothenberg ML, Berlin JD. Therapeutic strategies for metastatic colorectal cancer: simultaneous, sequential, or specific? J Clin Oncol 2003;21:3716-3717.
96. Rothenberg ML, Oza AM, Bigelow RH et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003;21:2059-2069.
97. Hurwitz H, Fehrenbacher L, Cartwright T et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proc Am Soc Clin Oncol 2003;22:3646a.
98. Hoff PM, Ansari R, Batist G et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001;19:2282-2292.
99. Van Cutsem E, Twelves C, Tabemero J et al. XELOX: mature results of a multinational, phase II trial of capecitabine plus oxaliplatin, an effective first-line option for patients with metastatic colorectal cancer. Proc Am Assoc Cancer Res 2003;22:1023a.
100. Bollina R, Beretta G, Toniolo D et al. Capecitabine (C) and irinotecan (i) (CAPIR1): a good combination in elderly patients (pts) with advanced colorectal cancer (ACRC) as first line chemotherapy (CT). Preliminary results of a phase II trial. Proc Am Soc Clin Oncol 2003;22:1332a.
101. Cunningham D, Humblet Y, Siena S et al. Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2003;22:1012a.
102. Salomon DS, Brandt R, Ciardiello F et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
103. Messa C, Russo F, Caruso MG et al. EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma. Acta Oncol 1998;37:285-289.
104. Mayer A, Takimoto M, Fritz E et al. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 1993;71:2454-2460.
105. Saltz LB, Meropol NJ, Loehrer PJ Sr et al. Phase II trial of cetuximabin patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-1208.
106. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-994.
107. Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-1006.
108. Kouroukis CT, Browman GP, Esmail R et al. Chemotherapy for older patients with newly diagnosed, advanced-stage, aggressive-histology non-Hodgkin lymphoma: a systematic review. Ann Intern Med 2002;136:144-152.
109. Lichtman SM. Aggressive lymphoma in the elderly. Crit Rev Oncol Hematol 2000;33:119-128.
110. Riechmann L, Clark M, Waldmann H et al. Reshaping human antibodies for therapy. Nature 1988;332:323-327.
111. McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-2833.
112. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242.
113. Habermann T, Weller E, Morrison VA et al. Rituximab-CHOP versus CHOP with or without maintenance rituximab in patients 60 years of age or older with diffuse large B-cell lymphoma (DLBCL): an update. Blood 2004;104:40a.
114. Pfreundschuh M, Truemper L, Kloess M et al. 2-weekly vs. 3-weekly CHOP with and without etoposide for patients >60 years of age with aggressive non-Hodgkin's lymphoma (NHL): results of the completed NHL-B-2 trial of the DSHNHL. Blood 2002;99(suppl 1):3060a.
115. Sundararajan V, Hershman D, Grann VR et al. Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study. J Clin Oncol 2002;20:173-178.
116. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
117. Neijt JP, Engelholm SA, Tuxen MK et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000;18:3084-3092.
118. Langer CJ, Manola J, Bernardo P et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002;94:173-181.
119. Lichtman SM, Buchholtz M, Marino J et al. Use of cisplatin for elderly patients. Age Ageing 1992;21:202-204.
120. Yamamoto N, Tamura T, Maeda M et al. The influence of ageing on cisplatin pharmacokinetics in lung cancer patients with normal organ function. Cancer Chemother Pharmacol 1995;36:102-106.
121. Wildiers H, Highley MS, de Bruijn EA et al. Pharmacology of anticancer drugs in the elderly population. Clin Pharmacokinet 2003;42:1213-1242.
122. Duffull SB, Robinson BA. Clinical pharmacokinetics and dose optimisation of carboplatin. Clin Pharmacokinet 1997;33:161-183.
123. Ozols RF. Optimum chemotherapy for ovarian cancer. Int J Gynecol Cancer 2000;10:33-37.
124. I24 Gronlund B, Hogdall C, Hansen HH et al. Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma. Cancer 2002;94:1961-1967.
125. Dizon DS, Hensley ML, Poynor EA et al. Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer. J Clin Oncol 2002;20:1238-1247.
126. Ozols RF. Recurrent ovarian cancer: evidence-based treatment. J Clin Oncol 2002;20:1161-1163.
127. Hainsworth JD, Burris HA 3rd, Litchy S et al. Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. A Minnie Pearl Cancer Research Network Phase II Trial. Cancer 2000;89:328-333.
128. Perez EA, Vogel CL, Irwin DH et al. Weekly paclitaxel in women age 65 and above with metastatic breast cancer. Breast Cancer Res Treat 2002;73:85-88.
129. Homesley HD, Hall DJ, Martin DA et al. A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients. Gynecol Oncol 2001;83:394-399.
130. Armstrong DK. Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity. The Oncologist 2004;9:33-42.
131. Seymour MT, Mansi JL, Gallagher CJ et al. Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease. Br J Cancer 1994;69:191-195.
132. Rocha Lima CM, Herndon JE 2nd, Kosty M et al. Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the Cancer and Leukemia Group B. Cancer 2002;94:181-187.
133. Hensing TA, Peterman AH, Schell MJ et al. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer 2003;98:779-788.
134. Sequist LV, Lynch TJ. Aggressive treatment for the fit elderly with non-small-cell lung cancer? Yes! J Clin Oncol 2003;21:3186-3188.
135. Gridelli C. The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study. The Oncologist 2001;6(suppl 1):4-7.
136. Gridelli C, Perrone F, Gallo C et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003;95:362-372.
137. Lilenbaum R. Management of advanced non-small-cell lung cancer in patients with a performance status of 2. Clin Lung Cancer 2004;5:209-213.
138. Lilenbaum R. Management of advanced non-small-cell lung cancer in elderly populations. Clin Lung Cancer 2003;5:169-173.
139. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
140. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103.
141. 12 and folate reduce toxicity of Alimta™(pemetrexed disodium, LY231514, MTA), a novel antifolate/antimetabolite. Proc Am Soc Clin Oncol 2001;20:300a.
142. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597.
143. Eli Lilly and Company. Alimta® [package insert]. Available at http://www.alimta.com. Accessed January 2, 2005.
144. Herbst RS, Prager D, Hermann R et al. TRIBUTE: A Phase III Trial of Erlotinib Hydrochlride (OSI-744) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non-Small Cell Lung Cancer. J Clin Oncol 2005;23:5892-5899.
145. Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small cell lung cancer: Current knowledge and future directions. J Clin Oncol 2005;23:2556-2568.
146. Johnson DH, Arteaga CL. Gefitinib in recurrent non-small-cell lung cancer: an IDEAL trial? J Clin Oncol 2003;21:2227-2229.
147. Cappuzzo F, Gregore V, Rossi E et al. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol 2003;21:2658-2663.
148. Arriagada R, Bergman B, Dunant A et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-360.
149. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.